Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.
Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.
复制标题
DOI：
10.4137/cmc.s17067
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Miura T
中科院分区：
文献类型：
--
作者：
Furuhashi M;Saitoh S;Shimamoto K;Miura T
在过去的十年中，代谢和炎症途径整合的证据，在代谢综合征的几个方面称为metaflammation，已经积累。脂肪酸结合蛋白4（FABP 4），也称为脂肪细胞FABP（A-FABP）或aP 2，主要在脂肪细胞和巨噬细胞中表达，并且在与炎症相关的胰岛素抵抗和动脉粥样硬化的发展中起重要作用。尽管缺乏典型的分泌信号肽，但FABP 4已被证明以与脂解相关的非经典途径从脂肪细胞释放，可能充当脂肪因子。循环FABP 4水平的升高与肥胖、胰岛素抵抗、糖尿病、高血压、心功能障碍、动脉粥样硬化和心血管事件相关。此外，FABP 4在几种类型的细胞和组织中的异位表达和功能最近已被证实。在这里，我们讨论了FABP 4在病理生理学方面的重要作用及其作为代谢和心血管疾病生物标志物的有用性。
Over the past decade, evidences of an integration of metabolic and inflammatory pathways, referred to as metaflammation in several aspects of metabolic syndrome, have been accumulating. Fatty acid-binding protein 4 (FABP4), also known as adipocyte FABP (A-FABP) or aP2, is mainly expressed in adipocytes and macrophages and plays an important role in the development of insulin resistance and atherosclerosis in relation to metaflammation. Despite lack of a typical secretory signal peptide, FABP4 has been shown to be released from adipocytes in a non-classical pathway associated with lipolysis, possibly acting as an adipokine. Elevation of circulating FABP4 levels is associated with obesity, insulin resistance, diabetes mellitus, hypertension, cardiac dysfunction, atherosclerosis, and cardiovascular events. Furthermore, ectopic expression and function of FABP4 in several types of cells and tissues have been recently demonstrated. Here, we discuss both the significant role of FABP4 in pathophysiological insights and its usefulness as a biomarker of metabolic and cardiovascular diseases.